Go here to listen to Dr. Lee Merritt discuss the history of parasites, biowarfare and cancer.
According to Merritt, the story of the CIA covering up the cure for cancer is pure bunk. The CIA didn’t exist when the truth about cancer was covered up. Merritt shows the proof–what we knew about cancer before 1930, and how Cancer research has been used–not just by us–as a cover for bioweapons research. And she believes it is actively being used as a bioweapon against us today.
The silver lining of COVID tyranny is that it affected nearly everyone in some form or fashion. Suffering has a way of opening eyes to the fact our government is not our friend, does not care about our well-being, and is in bed with Big Pharma – actually peddling their products for financial gain. Once you know this, things start making a lot more sense. Further, research institutions are beholden to this very corrupt, conflict riddled government for research grants which means they can’t be trusted either. The same goes for the academic publishing cartel. And lastly, the media is essentially a prostitute who will do anything for money, including accepting money from drug makers.
So, there you have it. The current lovely state of things.
With all of this said, it would be prudent to question everything our government, research, and media tells us because if they lie in one area, rest assured – they aren’t above lying in another area.
Our government health ‘experts’ attack anything that they don’t have their fingers on. There’s been a long, sordid history of the FDA attacking natural supplements, hormones, and anything Big Pharma considers a threat. Rather than addressing real issues like the excess levels of electromagnetic radiation, or ending the decades long addition of fluoride to water after research proves it lowers intelligence, our tax dollars are at work attacking safe treatments like homeopathy, supplements like NAC, natural thyroid hormones, and ivermectin – a proven, safe drug on the WHO list of essential medicines.
Which brings us to cancer – the massively lucrative elephant in the room.
Recently, a published cancer study linking the COVID shot to cancer simply disappeared. That’s right. Poof! Another cancer journal was hit with cyberattacks after confirming over 300 peer-reviewed COVID shot cancer cases across 27 countries. The evidence continues to pile up but no admissions are forth-coming, so don’t hold your breath.
But, there is some good news in this muddy pig-pen. Red-pilled, frustrated doctors are finding many alternativecancer treatments that appear to be working and have a much higher safety profile than current new treatments, which according to a new reviewonly help fewer than 2% of patients.
A few of these successful cancer treatments are anti-parasitic medications.
It’s important to learn about the history and Merritt is highly qualified to give that lesson. Go to top link to hear it.
Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol.
Methods: We analyzed a prospective observational cohort of 197 cancer patients who were prescribed ivermectin and mebendazole off-label through a telemedicine platform by licensed U.S. healthcare providers. Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. As part of a clinical program evaluation, data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) to evaluate self-reported cancer outcomes, medication adherence, and adverse events. 95% confidence intervals (CI) were calculated for primary outcome measures using the Wilson score method. Dose-stratified analyses for outcomes and safety were conducted using Chi-square statistics.
Results: The cohort represented a diverse clinical profile of cancer patients, with mean age of 67 years and nearly balanced sex distribution (52.3% male, 47.7% female). Cancer types included prostate (27.9%), breast (18.3%), lung (8.6%), colon (5.1%), urologic (4.6%), pancreatic (3.0%), liver (2.5%), gynecologic (2.5%), and hematologic (2.5%) malignancies. At enrollment, participants had a median duration since initial diagnosis of 1.2 years, with 37.1% experiencing active disease progression. At 6-month follow-up, medication adherence was high with 86.9% of participants completing the full initial 90-capsule ivermectin-mebendazole prescription and 66.4% remaining on the protocol at 6 months. The Clinical Benefit Ratio (CBR) was 84.4% (95% CI: 77.0–89.8%). Notably, 48.4% (95% CI: 39.7–57.1%) of the cohort reported the strongest positive outcomes, consisting of regression (15.6%; 95% CI: 10.2–23.0%) or no current evidence of disease (NED, 32.8%; 95% CI: 25.1–41.5%). Disease stability was reported to be maintained in 36.1% (95% CI: 28.1–44.9%) of participants, while 15.6% (95% CI: 10.2–23.0%) reported disease progression. While 25.4% reported mild side effects (primarily gastrointestinal), 93.6% of those affected continued treatment through minor dose adjustments. Some participants reported concurrent conventional therapies, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%), as well as adjunctive interventions such as supplement use (49.2%), dietary modification (37.7%), and other integrative approaches.
Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumor regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, given the observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials are warranted to validate these observations and further define optimal dosing strategies. (Go to link for full-length study)
Patients were prescribed the medications off-label through a telemedicine platform. They received compounded oral capsules containing:
25 mg of Ivermectin
250 mg of Mebendazole
The study noted that these were not strictly monotherapies. Many patients were undergoing concurrent conventional treatments, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%). Additionally, many used adjunctive interventions such as supplements (49.2%) and dietary modifications (37.7%).
Study Completion and Attrition
Of the initial 197 patients, 75 patients failed to complete the study (meaning they did not complete the 6-month follow-up survey).
A total of 122 participants completed the 6-month follow-up survey, resulting in a 61.9% response rate.
Among the 122 who responded, adherence was high: 86.9% completed the full initial 90-capsule prescription, and 66.4% chose to remain on the protocol at the 6-month mark.
Clinical Outcomes and Tolerability
The authors reported an overall Clinical Benefit Ratio (CBR) of 84.4% among the 122 patients who completed the survey. The self-reported outcomes broke down as follows:
No Evidence of Disease (NED):32.8%
Disease Stabilization:36.1%
Tumor Regression:15.6%
Disease Progression:15.6%
Within the article, Justuserhope asked AI to evaluate the benefit of adding one agent at a time from the RESET-5 Protocol(Mebendazole, ivermectin, sulforaphane, metformin, and aged garlic extract) to the Hulscher et. al study. The full RESET-5 reduces the likelihood of resistance development, enhances immune function, and depletes tumors of a critical survival tool – compensatory glutathione production.
The full RESET-5 Protocol boosts improvement even further by 30-40%.
_____________
**Comment**
For those of you studying this, 25 mg of ivermectin and 250mg of Mebendazole are considered pretty low dosages. Many patients are taking much more than that, so the fact they are getting such great improvement with such low dosages is fairly amazing. Lower dosages typically mean lower side-effects so this should be safe for nearly all to take. Share with your doctor and work together to get the best fit.
Resistance to chemotherapy and radiation is a well-documented challenge in oncology. Clinicians have increasingly reported that resistance can also emerge even when core repurposed drug metabolic cocktails are added to standard treatment regimens.
The Care Oncology Clinic’s 4-Drug COC Protocol — comprising Doxycycline, Atorvastatin, Mebendazole, and Metformin — represents a strong foundational approach to metabolic cancer therapy. In the METRICS trial, adding this protocol to standard of care in Glioblastoma was associated with nearly a one-year increase in survival.
The Problem of Resistance in Metabolic Protocols
Despite these promising results, resistance to the COC Protocol has been reported as well. The core problem lies in the nature of Cancer Stem Cells (CSCs): these cells are remarkably adaptable. When placed under primarily metabolic pressure, CSCs exploit alternative fuel sources and, given enough time, appear to reliably escape any single-axis metabolic attack.
Building a more powerful, resistance-prevention protocol requires a broader strategy — one that targets far more than cancer’s metabolism alone.
The RESET-5™ Protocol(Redox, Epigenetic, and Stem-cell Eradication Therapy)
Why it works:
The word “reset” profoundly captures what this protocol does compared to COC. While COC essentially attempts to starve the tumor, this protocol chemically resets the cancer’s mutated epigenome (via SFN), resets the gut microbiome (via AGE), and eradicates the root stem cells.
The RESET-5Protocol (Mebendazole, Ivermectin, Sulforaphane, Metformin, Aged Garlic Extract) represents a significant improvement over the traditional 4-drug Care Oncology Clinic (COC) protocol (Doxycycline, Atorvastatin, Metformin, Mebendazole).
While the COC protocol relies on broad metabolic starvation and mitochondrial toxicity, the RESET-5 protocol systematically targets cancer stem cell (CSC) networks, reverses epigenetic mutations, and modulates the redox environment without destroying the host’s immune system or microbiome.
The recent declassified documents linking a bioweapon program to Lyme disease, should be followed with a question: if they did this before in this area, have they done it in other areas?
The answer to this question is a resounding YES.
My first introduction to this topic was Dr. Garth Nicolson’s work and subsequent book, “Project Daylily,” chronicling the events surrounding ‘Gulf War Syndrome‘ suffered by over 150,000 veterans (and tens of thousands dead)
He changes all the names in the book but an astute student can figure out who he’s talking about – including the prestigious research institutions. He and his wife were targeted, poisoned and infected for the important work they were doing. They had to figure out how to treat a weaponized form of mycoplasma out of necessity as they both got it as well as their daughter.
“Cancer, AIDS, Weaponized Mycoplasmas & Gulf War Illness. Prof. Garth Nicolson’s hypothesis is straightforward: “The emergence of new illnesses and an increase in the incidence rate of previously described signs & symptoms are due to our toxic environment & the purposeful development & testing of Weapons of Mass Destruction.” Dr. Nicolson heads the Institute for Molecular Medicine. He spoke at the 9th Common Cause Medical Research Foundation Conference, Sudbury, Ontario, Canada on Aug. 29-31, 2008.”
It appears Germany is not alone in this endeavor…..
Dr. Lee Merritt: “Nazi Germany Hid Bioweapons Under Cancer Research And So Have We”
The former U.S. Navy physician claims parasite experiments linked to cancer may reveal how biological weapons research has been hidden inside legitimate medical programs.
She argues that similar research may have been weaponized and concealed within cancer research programs, drawing parallels to practices she says occurred in Nazi Germany.
Merritt also raises questions about how diet, vaccination, and parasite susceptibility might intersect.
“It only [works] if…[the] animals… [eat] a high-sugar diet or [are] vaccinated.”
“…in 1971, Nixon declared that we were going to stop the bioweapons offensive program in America. And we signed the treaty with I think 178 nations or something like that. We figured, we thought the Soviets turned around and violated it. And all sorts of people violated it. Well, probably everybody violated it, including us.
“But, in any case, the same time that we signed that treaty, he converted Fort Detrick [into a] bioweapons lab. He took it to HNHS to be part of the National Cancer Institute. And that happened in Nazi Germany. They hid their bioweapons under cancer research, and so have we.”
What if a cancer-causing bioweapon didn’t disappear after its original mission failed?
In these clips, Suzanne Humphries explores a Cold War plan to target Fidel Castro with an SV40-based cancer injection, and how the research may have quietly continued under the CIA and MD Anderson Cancer Center.
Humphries notes that in the 1960s, SV40 was actually weaponized in secret labs within the U.S., intended to be used as a bioweapon.
The story raises troubling questions about the origins of U.S. cancer research.
Watch the clips to hear Dr. Humphries break down the hidden history, the documents, and the people involved, because the more you uncover, the stranger and more shocking the story becomes.
“Today, SV40 is also part of that plasmid… used in many gene therapies… [and] for the [Covid] injection. Interestingly, in the 1960s, SV40 was… weaponized in secret labs… and the intention was to use it as a bioweapon… this is extremely well documented….”
(See link for article and video)
_____________
**Comment**
Thankfully, after decades of fruitless work, doctors awakened by COVID tyranny are now stepping forth saying cancer is a reversible metabolic disease. They are also providing successful treatments:
SAPI2022AONM_221203_013821 Go here for Eva Sapi’s slides titled, “Potential Connection of Borrelia Infection and Breast Cancer“. She also addresses “Mixed Biofilm in Other Infected Skin Tissues.” There is a particular slide that shows where in the human body that Borrelia biofilm is found.
Madison Area Lyme Support Group 